Since the approval of the first CTLA‐4 inhibitor ipilimumab for the treatment of metastatic melanoma in 2010,251 ICIs have brought new direction for tumor therapy and have shown powerful antitumor effects in HCC. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.